At a glance
Selected adult clinical studies cover obesity, heart-failure physiology and cardiovascular events. An adolescent registry result and an ex vivo placental study answer separate questions.
Identity & scope
Semaglutide is a GLP-1 receptor agonist. Evidence depends on the actual pharmaceutical preparation, study population and protocol, not the compound name alone.
What the research shows
- STEP 1 found greater average weight reduction with the studied semaglutide preparation plus lifestyle support than with placebo [1].
- SURMOUNT-5 found a larger average reduction with tirzepatide than semaglutide under its particular comparison [2].
- An adolescent trial posted descriptive BMI results comparing two care programmes with different counselling intensity [4].
- In a small heart-failure trial with obesity, exercise filling pressure was lower with semaglutide than placebo [6].
- A secondary analysis of the oral semaglutide SOUL trial reported fewer first and recurrent cardiovascular events in a high-risk population [7].
- A short laboratory experiment found fetal-side concentrations below the assay’s quantification limit in term placental tissue [8].
Critical interpretation
Read the comparison, population and preparation together
STEP 1 estimates a treatment effect in a defined population receiving lifestyle support, not an inherent percentage of weight loss attached to a molecule. SURMOUNT-5 improves on comparisons between separate trials by randomly assigning participants directly between two medicines, but it was open-label and compared particular tolerated clinical regimens. Its findings do not prove that one compound will be preferable for every outcome or every person. Neither trial provides a bridge from its controlled pharmaceutical preparation to a catalogue product with a different formulation or route. [1] [2]
The withdrawal extension changes the durability question
The STEP 1 extension adds a necessary qualification to an end-of-treatment headline: maintaining an effect after withdrawal is a separate research question. Average regain was substantial, but only a subset entered this exploratory follow-up. Both medication and structured lifestyle intervention stopped, so the design does not isolate the causal contribution of each change. Its 327 participants must not be mistaken for the original 1,961-person randomized population. This is valuable follow-up evidence, with different inferential strength from a new randomized continuation-versus-withdrawal trial. [3]
The adolescent trial compared two care programmes
The contrast concerns two programmes that differed in both medication and intensity of counselling. The posted results show the direction and size of the observed difference in average BMI change in those analysed. The open-label design, incomplete endpoint data and small serious-event counts limit the conclusions. This is a separate population from the adult STEP 1 trial. [4] [1]
REDEFINE 9 studied a specific combination
The study randomised adults to the two combination regimens or placebo within a dose level. The similar point estimates do not establish that the regimens are equivalent. The results cannot isolate either ingredient’s contribution or validate another preparation. [5]
Exercise congestion is a distinct clinical endpoint
Lower measured filling pressure helps explain a possible mechanism in this population. The study size and endpoint limit conclusions about admission rates, mortality and other heart-failure populations. [6]
Counting recurrent events changes the question
This analysis uses the original SOUL cohort to estimate total event burden, including recurrence. It supplies a complementary estimate rather than a new independent trial population. The effect estimate concerns the specified oral formulation alongside standard care. [7]
A placental perfusion model has a narrow scope
Below the quantification limit means the assay did not quantify transfer under those conditions. The model provides no information about developmental outcomes and cannot replace a pregnancy cohort. [8]
Bone findings in an animal model
The animal study reported differing effects on trabecular and cortical bone. The result is specific to an induced metabolic osteoporosis model. It cannot establish a fracture outcome or estimate the effect of semaglutide on bone in people. [9]
Limitations & uncertainties
- Neither trial tested HeartPep material, nasal formulations or equivalence between catalogue formats.
- Trial averages do not predict individual outcomes. Adverse events and treatment discontinuation matter alongside efficacy, and comparisons across unrelated trials can mislead.
Open research questions
- How do outcomes vary across populations and after treatment discontinuation?
- What formulation-specific quality, exposure and comparability evidence exists for any material under investigation?
Selected papers & source records
Download bibliography1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (opens in a new tab)
Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group (2021). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183 (opens in a new tab) · PMID 33567185
- Design & population
- 68-week randomized placebo-controlled trial in 1,961 adults without diabetes, with lifestyle intervention in both groups.
- What the study found
- Mean body-weight change was approximately -14.9% with semaglutide and -2.4% with placebo.
- Limits on interpretation
- A defined clinical preparation and selected population were studied. Gastrointestinal adverse effects were relevant; this is not evidence for catalogue-product equivalence.
2. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (opens in a new tab)
Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators (2025). New England Journal of Medicine. DOI: 10.1056/NEJMoa2416394 (opens in a new tab) · PMID 40353578
- Design & population
- 72-week open-label randomized comparison in 751 adults with obesity without diabetes.
- What the study found
- Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide; gastrointestinal events were common.
- Limits on interpretation
- Open-label, manufacturer-funded comparison of defined clinical preparations, without a placebo arm. It did not test commercial research-catalogue products.
3. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (opens in a new tab)
Wilding JPH, Batterham RL, Davies M, et al.; STEP 1 Study Group (2022). Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.14725 (opens in a new tab) · PMID 35441470
- Design & population
- Exploratory one-year off-treatment follow-up of 327 STEP 1 participants; study treatment and lifestyle intervention were both discontinued.
- What the study found
- Participants previously receiving semaglutide regained approximately two-thirds of their prior weight loss on average, with several cardiometabolic measures moving towards baseline.
- Limits on interpretation
- Selected extension subset, not a new randomized withdrawal comparison. Withdrawal of lifestyle support prevents assigning every observed change solely to drug withdrawal.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
4. Lifestyle Counseling and Medication for Adolescent Weight Management (NCT04873245) (opens in a new tab)
University of Minnesota (sponsor) (2026). ClinicalTrials.gov registry results.
- Design & population
- Open-label randomized phase 2 trial in 121 adolescents with severe obesity. It compared semaglutide plus less intensive behavioural counselling with intensive counselling alone. Registry results first posted 6 November 2026.
- What the study found
- At week 56, the posted mean BMI changes were −22.3% in the medication arm (58 analysed) and −1.8% with intensive counselling (50 analysed). Serious adverse events were reported in 1 of 60 and 2 of 61 participants, respectively.
- Limits on interpretation
- Sponsor-submitted results. The primary table does not display a between-group statistical analysis. The two groups had different counselling schedules, and some randomized participants were excluded from the primary measurements.
5. Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial (opens in a new tab)
Wharton S, Broholm C, Horn D, et al. (2026). The Lancet Diabetes & Endocrinology. DOI: 10.1016/S2213-8587(26)00275-5 (opens in a new tab) · PMID 43033821
- Design & population
- REDEFINE 9 (NCT06388187), a randomized phase 3b trial of two subcutaneous cagrilintide–semaglutide combinations versus placebo in 309 adults without diabetes. Published 14 November 2026.
- What the study found
- At week 68, the efficacy analysis estimated placebo-adjusted differences in weight change of −18.8 and −19.0 percentage points. Adverse events were common in all arms, mostly mild or moderate and gastrointestinal.
- Limits on interpretation
- Sponsor-funded. There was no single-component arm. The primary comparisons each tested an active regimen against placebo. Publisher abstract and accessible excerpts consulted.
6. Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial (opens in a new tab)
Borlaug BA, Jensen MD, Packer M, et al. (2026). Nature Medicine. DOI: 10.1038/s41591-026-04762-3 (opens in a new tab) · PMID 43000472
- Design & population
- Double-blind, randomized 52-week study in 81 adults with obesity and heart failure with preserved ejection fraction. Primary endpoint was invasively measured cardiac filling pressure during low-intensity exercise. NCT05371496.
- What the study found
- At 52 weeks, the estimate favoured semaglutide by 10.6 mmHg versus placebo (95% CI 8.0 to 13.3 mmHg lower).
- Limits on interpretation
- Small mechanistic study in a defined population. Publisher and PubMed abstracts consulted.
7. First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial (opens in a new tab)
Marx N, Deanfield JE, Mulvagh SL, et al. (2026). JAMA Cardiology. DOI: 10.1001/jamacardio.2026.4944 (opens in a new tab) · PMID 43013292
- Design & population
- Prespecified secondary analysis of SOUL (NCT03914326), a randomized oral semaglutide trial in 9,650 adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both.
- What the study found
- The analysis counted 683 first or subsequent major cardiovascular events with oral semaglutide and 791 with placebo (mean ratio 0.86, 95% CI 0.76–0.97). Adverse events led to discontinuation in 15.5% versus 11.6%.
- Limits on interpretation
- Sponsor-funded, secondary analysis of the original cohort. The studied oral formulation and high-risk population define the scope.
8. Evaluation of semaglutide in an ex vivo human placental perfusion model to estimate maternal-fetal transfer (opens in a new tab)
Chan E, Zabek M, Balluku A, et al. (2026). Placenta. DOI: 10.1016/j.placenta.2026.11.007 (opens in a new tab) · PMID 43025349
- Design & population
- Laboratory study using eight perfusions of isolated human term placental tissue under two exposure conditions.
- What the study found
- Semaglutide concentrations in the fetal-side perfusate were below the assay’s quantification limit in both conditions.
- Limits on interpretation
- Short ex vivo experiment in tissue from term pregnancies. PubMed abstract consulted. The result cannot establish absence of transfer in early pregnancy or clinical safety.
9. Weight loss at a cost: Semaglutide and PYY3-36 aggravate pre-existing metabolic osteoporosis in female Wistar rats (opens in a new tab)
Kloock S, Zytner P, Geiger N, et al. (2026). Bone. DOI: 10.1016/j.bone.2026.118170 (opens in a new tab) · PMID 43025770
- Design & population
- Controlled female rat study with an induced model of metabolic osteoporosis and separate semaglutide, PYY3-36 and combination groups.
- What the study found
- The semaglutide-only group showed a modest reduction in trabecular bone volume fraction. Trabecular changes were more pronounced in the PYY3-36 and combined groups. Cortical measures were unaffected.
- Limits on interpretation
- PubMed abstract consulted. The disease model, species and bone measurements limit translation to human bone health and clinical fracture risk.
10. Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation (opens in a new tab)
Aubrac G et al. (2026). Diabetes, Obesity and Metabolism. DOI: 10.1111/dom.71550 (opens in a new tab) · PMID 43010688
- Design & population
- Claims-based observational comparison of adults with overweight or obesity and atherosclerotic cardiovascular disease, without diabetes.
- What the study found
- The adjusted primary comparison did not detect a statistically significant difference in major adverse cardiovascular events between the two groups.
- Limits on interpretation
- This is not a randomized or equivalence trial. Residual confounding is possible, and the study does not establish interchangeability or the performance of a catalogue product.
11. Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes (opens in a new tab)
Doma M et al. (2026). American Heart Journal Plus: Cardiology Research and Practice. DOI: 10.1016/j.ahjo.2026.101003 (opens in a new tab) · PMID 43022342
- Design & population
- Propensity-matched retrospective TriNetX cohort of people with atherosclerotic cardiovascular disease and without diabetes.
- What the study found
- The analysis did not detect a statistically significant difference between the groups for the reported cardiovascular composite outcomes.
- Limits on interpretation
- Matching does not exclude residual confounding, and a null difference does not establish equivalence. Cohort overlap with other US database studies was not assessed. This is not evidence about any catalogue product.
Search & review scope
Targeted PubMed and ClinicalTrials.gov surveillance and review of the QUEST results tables. Also checked newly indexed or previously omitted original abstracts and identifiers.. Checked 20 November 2026.
Checked the registry methods, participant numbers, primary outcome and adverse-event counts against the existing adult clinical discussion. Reviewed the REDEFINE 9 publisher abstract and accessible article excerpts. Read the CAMEO-SEMA abstract from the publisher and PubMed. Reviewed the SOUL secondary paper’s accessible methods, results and limitations. Read the PubMed abstract for the term-placenta perfusion experiment. Checked a rat bone study at abstract level. Added selected human study records dated 2026, with study-specific limitations.
QUEST is registry-only in this review. Access varied by source and is labelled in the bibliography. Selected studies cannot establish effects across formulations, ages or pregnancy stages.
Recorded search terms
- PubMed: semaglutide, 6–16 November 2026 entry or publication dates
- ClinicalTrials.gov semaglutide results postings
- NCT04873245 QUEST adolescent weight management
- PMID 43033821 / DOI 10.1016/S2213-8587(26)00275-5
- PMID 43000472 / DOI 10.1038/s41591-026-04762-3
- PMID 43013292 / DOI 10.1001/jamacardio.2026.4944
- PMID 43025349 / DOI 10.1016/j.placenta.2026.11.007
- PMID 43025770 / DOI 10.1016/j.bone.2026.118170
- PMID 43010688 / DOI 10.1111/dom.71550
- PMID 43022342 / DOI 10.1016/j.ahjo.2026.101003
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. Semaglutide: literature review. HeartPep literature library. Reviewed 20 November 2026. https://heartpep.com/us/research/library/semaglutide.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.